BPTH

Bio Path Holdings Inc

NASDAQ

Add Alert

101

BPTH

Bio Path Holdings Inc

NASDAQ

Add Alert

101

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Awl416

04/18/24 3:16 PM

Post #6,377

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Monksdream PremiumMember

04/18/24 8:57 AM

Post #6,376

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

tw0122

04/18/24 7:23 AM

Post #6,375

New hi 3.85 700k float

Monksdream PremiumMember

04/10/24 1:41 PM

Post #6,374

Re: #6,372: @Awl416 - Volatility

BPTH new 52 lo

Monksdream PremiumMember

03/30/24 11:06 AM

Post #6,373

Re: #6,371: @Renee - BPTH: effective Feb. 23,2024 a one for 20

BPTH under $5

Awl416

03/25/24 10:11 AM

Post #6,372

Volatility

Renee

02/22/24 9:22 AM

Post #6,371

BPTH: effective Feb. 23,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

INV4

10/24/23 11:59 AM

Post #6,370

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

October 24, 2023

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML). The conference call will be held on Monday, October 30, 2023 at 9:00 a.m. ET.
The event will be hosted by Peter Nielsen, Chief Executive Officer of Bio-Path, and will feature presentations and discussion with:

Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta University
Maro Ohanian, D.O., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1 study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

https://ih.advfn.com/stock-market/NASDAQ/bio-path-BPTH/stock-news/92348612/bio-path-holdings-to-host-virtual-key-opinion-lead

$BPTH

INV4

10/23/23 11:36 AM

Post #6,369

Re: #6,368: @Triple nickle - Holding up pretty nice

Agree! Looking good.
$BPTH

Triple nickle Free

10/22/23 7:16 PM

Post #6,368

Holding up pretty nice

Huti

10/15/23 2:35 PM

Post #6,367

Re: #6,365: @webprods - $BPTH Finally I got answer where BPTH

12? We’ll see.. maybe once they get approved!

Zardiw

10/15/23 12:50 PM

Post #6,366

Re: #6,354: @Awl416 - OCG BPTH WTO who’s responsible?

$BPTH - #DDAmanda Video Analysis

#DDAmanda Halloween Special: https://DDAmanda.com/SignUpHalloween164.php

webprods

10/14/23 9:29 PM

Post #6,365

$BPTH Finally I got answer where BPTH going. Here you are: Target price $12. 1,500.00% up from today. Reason: FDA approval for drug ”Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc 2. Also Oct 11. 2023 News

Zardiw

10/14/23 7:42 PM

Post #6,364

Re: #6,357: @dinogreeves - BPTH will run big tomorrow.

+++ #DDAmanda Chart on: $BPTH :

DDAmanda lets you find these early:

Z

harry crumb Free

10/13/23 9:44 AM

Post #6,363

Out, halted. Beware of a selloff folks

TimeFades

10/13/23 4:10 AM

Post #6,362

Boom

dinogreeves PremiumMember

10/12/23 11:41 PM

Post #6,361

Re: #6,360: @jchords - Yea. Got in pretty low on the jump.

Good luck, I had this back in the day when it made that huge run. Been watching off and on.

jchords

10/12/23 11:34 PM

Post #6,360

Re: #6,359: @dinogreeves - They are waiting on from FDA for Fast

Yea. Got in pretty low on the jump. Don’t have many shares. Thanks for the info

dinogreeves PremiumMember

10/12/23 11:33 PM

Post #6,359

Re: #6,358: @jchords - You know what the catalyst is?

They are waiting on from FDA for Fast Track Designation, they applied back in August, so it takes 60 days after the request. Either there is leak somewhere out there or just hedge run. If there is news tomorrow, I expect a huge run, closed very strong after hours.

jchords

10/12/23 10:44 PM

Post #6,358

Re: #6,357: @dinogreeves - BPTH will run big tomorrow.

You know what the catalyst is?

dinogreeves PremiumMember

10/12/23 8:23 PM

Post #6,357

BPTH will run big tomorrow.

jchords

10/12/23 4:43 PM

Post #6,356

Going crazy AH

jchords

10/12/23 4:22 PM

Post #6,355

Re: #6,353: @Awl416 - Here we go again lol

Lol

Awl416

10/12/23 4:18 PM

Post #6,354

OCG BPTH WTO

who’s responsible?

Awl416

10/12/23 4:16 PM

Post #6,353

Here we go again lol

Monksdream PremiumMember

10/05/23 7:48 AM

Post #6,352

BPTH new 52 week low

REAGAN

08/18/23 2:46 PM

Post #6,351

I could buy controlling interest in this company for $2.4m. Fire the CEO. Phase II is years away from a successful P-3 double blind. Of which would cost $200m. What could happen here is a consortium could come in and buy up 50% of the shares then juice the pump and sell them at $3.00 a share. But yes. Looks absolutely terrible here.

Monksdream PremiumMember

08/16/23 12:31 PM

Post #6,350

BPTH new 52 Week low

TimeFades

08/08/23 4:44 PM

Post #6,349

Bingo

TimeFades

08/04/23 10:55 AM

Post #6,348

Re: #6,347: @TimeFades - Lol

Don’t get shook here this thang will have it’s day soon atlesst 50% bag

TimeFades

08/04/23 9:35 AM

Post #6,347

Re: #6,346: @willlbone - Blood Bath Holdings.

Lol

willlbone

08/03/23 1:53 PM

Post #6,346

Blood Bath Holdings.

AJ Freely

08/01/23 7:58 AM

Post #6,345

$BPTH - 👆Up 20% Pre-Market/ Current Price $1.29
👉Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

cfoofme

07/09/22 2:57 PM

Post #6,344

Re: #6,343: @cfoofme - Anyone here still holding BPTH?

Anyway, pps has been climbing slowly & steadily the last month.

cfoofme

07/08/22 7:30 PM

Post #6,343

Anyone here still holding BPTH?

mik1234

10/22/21 10:51 PM

Post #6,342

86,231 shares traded today.

INFINITI

08/30/21 7:22 AM

Post #6,341

BPTH $$$

mik1234

08/27/21 2:46 PM

Post #6,340

BPTH

mik1234

08/26/21 6:22 AM

Post #6,339

BPTH

Pt3

08/24/21 4:11 PM

Post #6,338

Re: #6,336: @INFINITI - Nice

kool i hope this start running fda clear

INFINITI

08/24/21 3:32 PM

Post #6,337

AH will be interesting not selling $$$$$

INFINITI

08/24/21 3:32 PM

Post #6,336

Re: #6,334: @Pt3 - kool got filled 6.32 ??

Nice

Hercules1

08/24/21 3:24 PM

Post #6,335

Tomorrow this blows right by $9

Pt3

08/24/21 3:07 PM

Post #6,334

Re: #6,333: @INFINITI - Hasn’t been blood all day nothing but green $$$$$$

kool got filled 6.32 ??

INFINITI

08/24/21 3:05 PM

Post #6,333

Re: #6,332: @Pt3 - BLOOD EVRR

Hasn’t been blood all day nothing but green $$$$$$

Pt3

08/24/21 1:49 PM

Post #6,332

BLOOD EVRR

INFINITI

08/24/21 9:47 AM

Post #6,331

Cmon wtf

INFINITI

08/24/21 9:04 AM

Post #6,330

Back to 52wk high let’s goooo$$$

INFINITI

08/24/21 8:45 AM

Post #6,329

Breaking out today ENJOY$$$$!

make it happen Free

08/24/21 8:40 AM

Post #6,328

Profitability
Profit Margin 0.00%
Operating Margin 0.00%

Management Effectiveness
Return on Assets -25.12%
Return on Equity -42.71%

Cash Flow Statement
Operating Cash Flow -9.17M
Levered Free Cash Flow -5.47M

Older

Bio Path Holdings Inc (BPTH)

Followers	101	Posters	339
Posts (Today)	0	Posts (Total)	6377
Created	03/26/13	Type	Free
Moderators

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001, known as Prexigebersen has completed a partial phase II combination trial (with LDAC). The interim results demonstrated 47% of the patients showed early anti-leukemic activity.

http://www.biopathholdings.com/wp-content/uploads/2018/04/BPTH_Interim_Phase_2_AML_Data_Release.pdf

The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.

A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.

Patent protection for manufacturing their neutral lipid delivery system has been granted.

http://www.biopathholdings.com

This link to the company website describes their delivery technology:

http://biopathholdings.com/technology/

The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.

Bio-Path Holdings does not manufacture their drugs but uses contractors, hence the need for partners.